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Objective: The diagnosis of neurocysticercosis (NCC) remains problematic because of the heterogeneity of its clinical,
immunological, and imaging characteristics. Our aim was to develop and assess a new set of diagnostic criteria for NCC,
which might allow for the accurate detection of, and differentiation between, parenchymal and extraparenchymal
disease.
Methods: A group of Latin American NCC experts developed by consensus a new set of diagnostic criteria for NCC.
A multicenter, retrospective study was then conducted to validate it. The reference standard for diagnosis of active
NCC was the disappearance or reduction of cysts after anthelmintic treatment. In total, three pairs of independent
neurologists blinded to the diagnosis evaluated 93 cases (with NCC) and 93 controls (without NCC) using the new
diagnostic criteria. Mixed-effects logistic regression models were used to estimate sensitivity and specificity.
Results: Inter-rater reliability (kappa) of diagnosis among evaluators was 0.60. For diagnosis of NCC versus no NCC, the
new criteria had a sensitivity of 93.2% and specificity of 81.4%. For parenchymal NCC, the new criteria had a sensitivity
of 89.8% and specificity of 80.7% and for extraparenchymal NCC, the new criteria had a sensitivity of 65.9% and specific-
ity of 94.9%.
Interpretation: These criteria have acceptable reliability and validity and could be a new tool for clinicians and researchers.
An advantage of the new criteria is that they consider parasite location (ie, parenchymal or extraparenchymal), which is an
important factor determining the clinical, immunological, and radiological presentation of the disease, and importantly, its
treatment and prognosis.
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Neurocysticercosis (NCC), the most common parasit-ic disease of the central nervous system (CNS), is
still a cause of unacceptable morbidity and mortality in
endemic areas.1,2 It is also an emerging public health
problem in high-income countries.3–5 A current concern
is that its prevalence remains unknown because there are
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problems inherent to its diagnosis.6,7 Diagnostic criteria
for NCC were proposed in 2001.8 These have not yet been
validated, but they have nevertheless made an important
contribution to improving the knowledge of NCC. These
proposed criteria, however, lack operational definitions and
include a complex body of categories and degrees of cer-
tainty that can be difficult to apply in clinical practice.
They may be useful in identifying individuals with paren-
chymal forms of NCC, but have limited use for people
with extraparenchymal NCC.9 A broad consensus suggests
that these criteria should be revised to incorporate current
state-of-the-art scientific knowledge about NCC.5,10–12
From the clinical, immunological, and pathophysio-
logical points of view, parenchymal and extraparenchymal
NCC are distinct entities,5,12,13 which cannot be covered
by a single set of diagnostic criteria. To improve diagnosis
of NCC, a panel of neurologists and neurosurgeons from
Latin American countries endemic for NCC aimed to
propose new diagnostic criteria for symptomatic NCC.
The purpose of the exercise was to simplify the diagnostic
criteria and clarify definitions currently used in the diag-
nosis, allowing them to be used by practicing physicians
and adapted, as necessary, for epidemiological studies and
clinical trials. While refining the diagnostic criteria to
reflect improved understanding of the disease and new
technologies, the panel retained all useful features of the
existing diagnostic criteria.
The objective was first to establish a consensus
among clinical experts on the most significant diagnostic
criteria for NCC and then evaluate the reliability and
validity of these new diagnostic criteria.
Materials and Methods
Phase 1. Developing Consensus Diagnostic
Criteria
A panel of Latin American neurologists and neurosurgeons
(R.A. [Brazil], J.C.D. [Bolivia], J.F. [Colombia], Ecuador
[A.C.], and Mexico [A.F.]) was set up. Symposia were held from
June 2011 to July 2013, including additional experts. One hun-
dred fifty consecutive individuals with newly suspected NCC
were pooled by the panel members from their own departments.
On the basis of the discussions and analysis of epidemiological,
clinical, immunological, and imaging findings of these 150 peo-
ple, a proposal for a new set of criteria was drafted. The panel
members further evaluated these criteria and incorporated modi-
fications, until consensus was achieved on the new criteria (Table
1) and their operational definitions, to be further validated in
the second phase of this study. The operational definitions were
as follows:
Parenchymal neurocysticercosis. Parasites located in the
parenchyma or in the subarachnoid space of the convexity
or in the sulcus of the convexity. We grouped these three
locations under the term “parenchymal” as their clinical
(mainly seizures and headache), immunological (detection
of antibodies and antigens is lower than in extraparenchy-
mal forms), and cerebrospinal fluid (CSF) characteristics
(CSF cells, proteins, and glucose concentration are fre-
quently normal) are similar. Commonly used imaging tools
(computed tomography [CT] and magnetic resonance
imaging [MRI]) cannot differentiate them, particularly
when parasites are located at the bottom of a sulcus.
Extraparenchymal neurocysticercosis. Parasites located in the
basal cisterns of the subarachnoid space or in the ventricular
system (intracranial hypertension is the main symptom).
These two locations share clinical and immunological
aspects (positive detection of antigens and antibodies) and
their CSF (inflammatory) has the same anomalies.
Cysticercus with pathological diagnosis. The finding of par-
asites in brain biopsy, according to classical pathological
descriptions.14
Neuroimaging definitions. CT and MRI identify the four
developmental phases of cysticerci (vesicular or viable
phase, colloidal and granular-nodular in the degenerative
phases, and calcified phase or dead parasite) when located
in the parenchyma.1 Cysts in the vesicular phase appear
as circumscribed, rounded, hypodense (or hypointense)
areas, without enhancement by contrast media. In the
MRI, the vesicular larva appears with a CSF-like intensi-
ty signal on all sequences, with no surrounding high sig-
nal on T2-weighted images. Both MRI and CT may
show a high intensity or hyperdense, 2- to 3-mm mural
nodule depicting the scolex, in the interior of some vesic-
ular cysts. In the degenerative phases, contrast enhanced
CT scan shows an annular (colloidal phase) or nodular
(granular-nodular phase) enhancement surrounded by
irregular perilesional edema. In these degenerative phases,
the fluid content gives a slightly higher signal than CSF,
sometimes isodense with the parenchyma on MRI-T1
and/or proton density-weighted images, and a high signal
on T2 images. The capsule shows a higher signal than
the adjacent brain, with thick ring enhancement on T1
images, whereas on T2 images there is a low ring signal
surrounded by high signal, attributed mostly to edema.
In the calcified phase, a nodule of homogenous high
density on CT, or low intensity on proton-weighted
MRI, is visualized.15,16 Parasites located in the subarach-
noid space or inside the ventricular system emit an inten-
sity signal similar to that of the CSF and commonly lack
a visible scolex. Usually, there is no enhancement after
the administration of intravenous contrast. Specific MRI
sequences including diffusion-weighted MRI magnetiza-
tion transfer ratio, three-dimensional (3D) constructive
interference in steady state, fast imaging employing
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steady-state acquisition sequences (FIESTA), and fluid-
attenuated inversion recovery sequences have therefore
been recommended for visualization of the cyst wall and,
potentially, the scolex.17,18
Positive immunological tests. The enzyme-linked immuno-
sorbent assay (ELISA) and enzyme-linked immunoelec-
trotransfer blot (EITB) assay are used, either in sera or in
CSF. EITB19 detects antibody whereas ELISA20 can be
TABLE 1. New Diagnostic Criteria for Symptomatic Neurocysticercosis
1. Parenchymal neurocysticercosis
Definitive parenchymal neurocysticercosisa, one of the following:
1. Parenchymal cyst with pathological diagnosis
2. Single or multiple active parenchymal cysts, with at least one cyst with scolex on CT or MRI
3. Multiple parenchymal vesicles without scolex associated with at least one of the following:
a. Seizures: focal or generalized tonic-clonic
b. Positive serum or CSF immunological test (ELISA, EITB)
4. Any combination of the parenchymal cysticercus in different evolutive stages: vesicular with or without scolex,
degenerative (colloidal or nodular), and calcified
Probable parenchymal neurocysticercosis, one of the following:
1. Single parenchymal calcification or vesicle (without scolex) or degenerating cyst(s), establishing differential diagnoses
with other etiologies, associated with at least two of the following:
a. Seizures: focal or generalized tonic-clonic
b. Subcutaneous or muscle cysts location confirmed by biopsy
c. Positive serum or CSF immunological test (ELISA, EITB)
d. Plain X-ray films showing “cigar-shaped” calcifications
e. Individual who lives or has lived in or has traveled frequently to endemic countries
2. Multiple parenchymal calcifications in an individual who lives or has lived in or has traveled frequently to
endemic countries and in whom clinical state excludes other etiologies of calcifications
2. Extraparenchymal neurocysticercosis (intraventricular/basal subarachnoid)
Definitive extraparenchymal neurocysticercosis, one of the following:
1. Extraparenchymal cyst with pathological diagnosis
2. One or more extraparenchymal cysts on MRI special sequences with scolex in at least one of them
3. One or more extraparenchymal cysts on MRI special sequences without scolex associated with
at least two of the following:
a. Hydrocephalus
b. Inflammatory CSF
c. Positive CSF immunological test (ELISA, EITB)
d. Presence of single or multiple calcifications or parenchymal vesicular or degenerative cyst
3. Definitive parenchymal and extraparenchymal neurocysticercosis
Combination of the above definitive parenchymal and definitive extraparenchymal criteria
aParasite located in the subarachnoid space of the convexity are included with parenchymal parasites.
CT5 computed tomography; MRI5magnetic resonance imaging; CSF5 cerebrospinal fluid; ELISA5 enzyme-linked immunosorbent assay;
EITB5 enzyme-linked immunoelectrotransfer blot.
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used to detect either specific antibody or antigen.
Regarding detection of antibodies, although the results
differ between studies, their sensitivity seems to be higher
in sera of people with parenchymal parasites, whereas in
people with extraparenchymal ones, sensitivity and specif-
icity are higher in CSF.21 Detection of antigens is mainly
positive in cases of viable extraparenchymal cysts; its sen-
sitivity is slightly higher in CSF than in sera.
Seizures and epilepsy. Definitions are based on the recommen-
dation of the International League Against Epilepsy.22,23
Subcutaneous or muscle cysts location confirmed by biopsy.
Cysticerci in subcutaneous tissue have the appearance of
spherical, smooth, mobile, and firm swellings, 1 to 2cm
in diameter, painless, and noninflammatory. Histological
sections show the scolex with its suckers and hooks, or
the presence of parasitic membranes.14
“Cigar shaped” calcifications. Plain X-ray films show mul-
tiple oval, or cigar-shaped, muscular calcifications present
throughout the upper and lower extremities, which corre-
sponds to cysticerci located outside the CNS.
Endemic countries. Those countries in which the life cycle
of the parasite can be reproduced, attributed to the pres-
ence of free-roaming pigs, absence of adequate disposi-
tion of human feces and of sanitary control, and scarcity
of potable water.
Hydrocephalus. A disturbance of CSF formation, flow, or
absorption, leading to an increase in the volume occu-
pied by this fluid in the CNS.24
Inflammatory CSF. Lymphocytic pleocytosis (between 15
and 300 cells per ml, 80–100% lymphocytes), mild
elevation of protein (between 50 and 300mg/dl), and
hypoglycorrhachia (CSF glucose <40mg/dl).25
Phase 2. Reliability and Validity of the
Instrument
We evaluated the new diagnostic criteria in a multicenter, retro-
spective case-control study, adhering to the Standards for Report-
ing of Diagnostic Accuracy criteria.26 The study was initially
approved by the ethical committee of the “Instituto Nacional de
Neurologıa y Neurocirugıa,” Mexico City, Mexico, and then local
approval from each institution was obtained.
REFERENCE STANDARD. To differentiate between cases and
controls, we used a reference standard. The only “gold standard”
of NCC is the anatomopathological study, which is generally
unavailable; the panel therefore considered that “response to cysti-
cidal treatment” could be a reliable “reference standard.” All indi-
viduals with a cystic image (ie, viable parasites) included in this
study therefore needed to receive cysticidal treatment and to have
had post-treatment imaging studies (CT scan or MRI). Individu-
als in whom the post-treatment study showed evident changes in
the cystic image (ie, disappearance or reduction of cysts) were
considered to be cases, whereas those in whom no changes were
observed were included as controls. Individuals with calcified (ie,
inactive) parasites were also included as cases if pretreatment
radiological studies detected a viable parasite that calcified after
treatment. The cysticidal treatment used was albendazole 15 to
30mg/kg/day for 10 days with corticosteroids (mostly prednisone
1mg/kg/day). Pre- and post-treatment radiological studies were
interpreted by experienced neuroradiologists, who evaluated the
presence of changes in the images. Individuals with only calcifica-
tions were included as cases if pretreatment radiological studies
detected a viable parasite that calcified after treatment. Individuals
included as controls, because they fulfilled inclusion criteria for
clinical manifestations or immunological testing (one or three of
the inclusion criteria below) and had normal imaging, did not
receive cysticidal treatment, because there was no reason to treat
them.
Cases (individuals with confirmed NCC diagnosis) and
controls (individuals with clinical, immunological, or imaging
features compatible with NCC, but in whom NCC was exclud-
ed), were consecutively selected by review of medical charts of
individuals seen in the previous 10 years. Some of them were
included in clinical trials to evaluate efficacy of anthelminthic
treatment in individuals with active NCC.27 No individuals
included in this phase had been included in phase 1.
Individuals suitable for inclusion as cases or controls were
initially selected according to the following inclusion and exclu-
sion criteria:
Inclusion criteria. Individuals with at least one of the fol-
lowing criteria:
1. Clinical manifestations: people with focal seizures or gener-
alized tonic-clonic seizures, or adults (>16 years old) with
intracranial hypertension or hydrocephalus.
2. Imaging (CT or MRI): any cyst (vesicular or colloidal) or
granular-nodular or calcified lesion1 in parenchymal or
extraparenchymal location.
3. Immunological testing: individuals with positive tests EITB
or ELISA in serum or CSF.19–21
A neuroimaging study was mandatory for those meeting
criteria 1 or 3.
Exclusion criteria. Individuals in whom clinical, immuno-
logical, or imaging data were doubtful and could not be classi-
fied with certainty as cases or controls.
We organized three pairs of evaluators, blinded to all
diagnoses, with the objective of determining reliability between
pairs of evaluators and validity in two separate evaluations of
the participants (Supplementary Table 1). The evaluators were
neurologists from Brazil, Ecuador, and Mexico and were inde-
pendent of the panel that developed the criteria. An anonymous
database was set up containing the following information for
cases and controls: clinical symptomatology; CSF characteristics
(cell count and the percentages of lymphocytes, neutrophils and
eosinophils, proteins, and glucose concentration); and results of
immunological assays for antibodies and antigens. Pretreatment
CT and MRI of all cases and controls were also collected. Each
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of three pairs of the evaluators received a random sample of
one third of the individuals (ie, cases and controls) included.
The database of clinical information and images for these indi-
viduals was sent to the three pairs of evaluators, with each pair
reviewing the same participants. Each evaluator in each pair
reviewed the individual’s images and clinical information and
made diagnoses based on the newly proposed criteria and on
the 2001 criteria.8 The same number of cases and controls of
each of the participant countries was sent to each of the pair of
evaluators.
Statistical Analysis
To compare the demographic and clinical characteristics of the
cases and controls, we used the Mann–Whitney U test for the
continuous variable (ie, age) and Pearson’s chi-square tests (or
Fisher’s exact test, if appropriate) for all categorical variables.
Cohen’s kappa coefficient was used to evaluate inter-rater reli-
ability of the proposed criteria between each pair of evaluators,
comparing diagnoses of NCC (including probable/definitive
parenchymal and extraparenchymal disease) versus no NCC.
An overall kappa was calculated by pooling the responses for
the first evaluation of all participants (ie, the results of reviewers
1, 3, and 5 for all 186 participants) and comparing this with
the pooled responses for the second evaluation of all partici-
pants (ie, the results of reviewers 2, 4, and 6 for all 186
participants).
To evaluate sensitivity and specificity, an estimated sample
size of 93 cases and 93 controls per evaluation was included,
assuming an expected sensitivity or specificity of 95% with a
lower acceptable confidence interval (CI) of 85%,28 which was
based on expert clinical opinion, because there were no previous
studies setting a precedent. We used mixed-effects logistic
regression models to determine sensitivity and specificity. We
fitted one main model that included covariates for the new cri-
teria, the 2001 criteria, and gold-standard diagnosis, with test
diagnosis (ie, NCC vs no NCC) as the outcome. Random
effects in the model were individual reviewer and study partici-
pant. For the new criteria, we fitted two additional mixed-
effects logistic regression models, for parenchymal NCC and
extraparenchymal NCC separately, with test diagnosis as the
outcome (ie, parenchymal or extraparenchymal NCC vs no
NCC) and gold-standard diagnosis as the predictor, with
reviewer and study participant as random effects. When deter-
mining the sensitivity and specificity of the new criteria for
parenchymal NCC, all cases with exclusively extraparenchymal
NCC were excluded from the analysis, and, similarly, when
determining sensitivity and specificity for extraparenchymal
NCC, all cases with exclusively parenchymal NCC were exclud-
ed. This was done in an effort to only compare participants
with either parenchymal or extraparenchymal NCC with partic-
ipants without NCC (ie, controls). All analyses were done using
SAS software (version 9.4; SAS Institute Inc., Cary, NC).
Results
Participants
We reviewed 250 consecutive individuals fulfilling the
inclusion criteria, aiming to identify 93 cases and 93
controls. Once these numbers were reached, no further
charts were reviewed. In total, 208 individuals were iden-
tified (Fig 1), but 22 were excluded because there was
uncertainty associated with their diagnosis.
The 93 cases included originated from Ecuador
(N5 26), Brazil (N5 29), and Mexico (N5 38). Para-
site location was mainly parenchymal (N5 52; 55.9%),
followed by extraparenchymal (N5 31; 33.3%) and in
both locations (N5 10; 10.8%). In those with extrapar-
enchymal NCC, parasites were in the subarachnoid space
in 20 (48.8%) individuals, in the ventricular system in
18 (43.9%), and in both compartments in 3 (7.3%).
For controls, 93 neurological cases fulfilling the
inclusion criteria were included from Mexico (N5 55),
Ecuador (N5 25), Brazil (N5 10), and Bolivia (N5 3).
Most of the 93 controls had a cystic lesion on imaging
(N5 49; 52.7%), which were congenital subarachnoid
cysts (N5 17; 34.7%), tumors (N5 14; 28.6%), ence-
phalomalacia (N5 7; 14.3%), Virchow-Robin space
(N5 6; 12.2%), and choroid plexus cysts (N5 5;
10.2%). The next most common inclusion criterion was
seizures (N5 36; 38.7%), followed by hydrocephalus
(N5 8; 8.6%).
Table 2 shows the main demographic and clinical
characteristics of the cases and controls. There were no
significant differences in age and sex between them.
Intracranial hypertension was more frequent in cases
compared to controls, and focal deficits were more fre-
quent in controls compared to cases, whereas the other
symptoms were similarly represented in the two groups.
Cytological and chemical analysis of CSF was avail-
able for 83 cases (89.2%) and 39 controls (41.9%).
FIGURE 1: Study design for recruitment of individuals with
and without NCC.Overall, 186 individuals were included in
our study. Using the reference standard, 93 participants had
NCC and 93 did not. The clinical, immunological, and imag-
ing information of the 186 individuals was reviewed by
three pairs of external evaluators, each of them reviewing
one third of the participants. Using the new diagnostic crite-
ria, these evaluators classified the individuals as having NCC
or not. NCC5neurocysticercosis.
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ELISA in CSF was performed in 57 cases (61.3%) and
21 controls (22.6%). ELISA in CSF was positive in 43
cases (75.4%) and negative in all controls. In serum,
ELISA was performed in 27 cases (29.0%) and in 3 con-
trols (3.2%); 25 cases (92.6%) and 1 control (33.3%)
were positive.
Reliability and Validity
Inter-rater reliability of the criteria for agreement
between NCC and no NCC, as determined by Cohen’s
kappa coefficient, ranged from 0.58 to 0.61, depending
on review pair, and was 0.60 overall. Supplementary
Table 2 summarizes the agreement between the two
members of each of the three pairs of evaluators, each
pair evaluating one third of the participants. Inter-rater
reliability for the 2001 criteria8 was 0.57 overall (data
not shown).
For the new criteria, sensitivity was 93.2% (95%
CI: 86.8, 99.6) and specificity was 81.4% (95% CI:
67.1, 95.6; Table 3). For the 2001 criteria,8 sensitivity
was 93.6% (95% CI: 87.6, 99.7) and specificity was
81.1% (95% CI: 66.7, 95.4). Differences between crite-
ria in sensitivity and specificity were negligible and not
significantly different (difference in sensitivity: 0.04%;
p5 0.85; difference in specificity: 0.03%; p5 0.95). Sen-
sitivity and specificity of the new criteria for parenchymal
NCC were 89.8% (95% CI: 81.2, 94.7) and 80.7%
(95% CI: 71.1, 87.6), respectively, and for extraparen-
chymal NCC, they were 65.9% (95% CI: 49.5, 79.3)
and 94.9% (95% CI: 89.4, 97.7), respectively (Table 3).
Because the 2001 criteria do not make the distinction
between parenchymal and extraparenchymal NCC,8 it
was not possible to evaluate its validity for these sub-
groups. Among all pairs of evaluators, only 43.9% (18 of
41) of individuals with extraparenchymal parasites were
diagnosed as having definitive NCC using the 2001
criteria.8
Discussion
Since the publication of the first diagnostic criteria for
NCC,8 new diagnostic tools have emerged and advances
made in the understanding of NCC pathophysiology. It
is now evident that parenchymal and extraparenchymal
NCC are distinct entities with regard to diagnosis and
treatment.13 Thus, we designed a practical and user-
friendly diagnostic tool that maintains scientific rigor,
but can also be used by the practicing physician in clinic
and for research. We then evaluated reliability and
TABLE 2. Demographics and Clinical Characteristics of Study Population
Cases (n5 93) Controls (n5 93) p
Mean age, yr (SD) 39.3 (13.9) 42.8 (19.9) 0.46a
Male sex, n (%) 41 (44.1) 44 (48.9) 0.51b
Country of origin, n (%)
Brazil 29 (31.2) 10 (10.8) 0.0009c
Mexico 38 (40.9) 55 (59.1)
Ecuador 26 (28.0) 25 (26.9)
Bolivia 0 (0.0) 3 (3.2)
Symptoms, n (%)d
Seizures 54 (58.1) 50 (55.6) 0.73b
Headache 38 (40.9) 32 (35.6) 0.46b
Intracranial hypertension 33 (35.5) 9 (10.0) <0.0001b
Focal deficits 13 (14.0) 23 (25.6) 0.05b
Neuropsychiatric manifestations 13 (14.0) 8 (8.9) 0.28b
aMann–Whitney U test.
bChi Square test.
cFisher’s exact test.
dSymptom data were missing for 3 controls.
SD5 standard deviation.
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validity of these new criteria. Overall, our results showed
acceptable inter-rater reliability, based on a kappa of 0.60
(kappa 0.61–0.805 substantial strength of agreement;
kappa of 0.41–0.605moderate strength of agreement;
kappa of 0.005 chance agreement).29 Next, we measured
validity, which was also acceptable, with similar sensitivi-
ties and specificities for NCC overall and for parenchy-
mal disease, but higher specificity and lower sensitivity
for extraparenchymal disease.
An attribute of the new criteria is that it permits
the distinction between parenchymal and extraparenchy-
mal NCC. Using the new criteria, there was high sensi-
tivity (89.8%) and specificity (80.7%) for detecting
parenchymal disease and lower sensitivity (65.9%), but
higher specificity (94.9%) for detecting extraparenchymal
NCC. Reliability and validity were acceptable for clinical
practice, but we would expect that routine use of 3D
MRI sequences (eg, FIESTA) would improve sensitivity,
particularly for extraparenchymal NCC.16–18,30 Further
studies with these new MRI sequences, however, as well
as a wider use of CSF analysis, are needed.31,32 Forty-one
people had extraparenchymal parasites, of whom only 18
(43.9%) would have been diagnosed with definitive
NCC using the 2001 criteria.8 In contrast, the new diag-
nostic criteria allowed an accurate diagnosis of definitive
extraparenchymal NCC in the majority of them. A possi-
ble explanation for this improved ability to diagnose
extraparenchymal NCC is that the new criteria have spe-
cific criteria (eg, hydrocephalus or positive CSF immuno-
logical test) compared with the very broad, nonspecific
2001 criteria8 (eg, clinical manifestation “suggestive” of
NCC, positive immunological test for anticysticercal
antibodies). Presence of antibodies in peripheral circula-
tion may suggest previous systemic infections, but not
necessarily active CNS infection.1,5 It has therefore been
proposed that detection of antigens, which are very spe-
cific for viable infection, should also be included as an
additional diagnostic criterion because its detection in
CSF is specific to CNS infection.5,11
These findings are important given the different
prognosis and treatment approach of parenchymal and
extraparenchymal NCC. In general, parenchymal NCC
has a good prognosis given that seizures, the main symp-
tomatology, usually remit and refractory epilepsy rarely
develops.13,33 In contrast, extraparenchymal NCC may
cause permanent sequelae, such as cognitive problems
and hydrocephalus, with a risk of death.10,25 Higher
doses of cysticidal drugs and longer anti-inflammatory
treatment are frequently required.34–36 In this context,
the high specificity of these new criteria is of great rele-
vance, demonstrating that the risk of false-positive diag-
nosis is low.
Strengths of this study include that it was multicen-
ter and incorporated different Latin-American sites where
NCC is endemic, with heterogeneity in the population
assessed as they come from general hospitals and tertiary
referral institutions. A practical reference standard was
also developed and used. Our study also has limitations.
Specifically, our specificity and its precision were lower
than we anticipated estimating our sample size; there
TABLE 3. Sensitivity and Specificity of New Diagnostic Criteria and 2001 Diagnostic Criteria
New Diagnostic Criteria 2001 Diagnostic Criteria
NCC overalla (N5 186)
Sensitivity, % (95% CI) 93.2 (86.8, 99.6) 93.6 (87.6, 99.7)
Specificity, % (95% CI) 81.4 (67.1, 95.6) 81.1 (66.7, 95.4)
Parenchymal NCCb (N5 155)
Sensitivity, % (95% CI) 89.8 (81.2, 94.7) NA
Specificity, % (95% CI) 80.7 (71.1, 87.6) NA
Extraparenchymal NCCc (N5 134)
Sensitivity, % (95% CI) 65.9 (49.5, 79.3) NA
Specificity, % (95% CI) 94.9 (89.4, 97.7) NA
aNCC overall includes definitive/probable parenchymal NCC and definitive extraparenchymal NCC for the new criteria and any NCC diagnosis
for the 2001 criteria.
bParticipants with only extraparenchymal NCC excluded. Parenchymal NCC is inclusive of probable and definitive categorizations.
cParticipants with only parenchymal NCC excluded.
NCC5 neurocysticercosis; CI5 confidence interval; NA5 not applicable.
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was, however, no precedent for this. Carrying out two
evaluations of the same participants increased our statisti-
cal power and despite our results being useful, a larger
sample size with different proportions of cases and con-
trols should be used in future studies, based on our
precedent. Future studies to evaluate these criteria should
also be prospective to minimize potential selection bias.
The cases and controls in this study had varying amounts
of clinical information (eg, immunological tests or CSF
analysis) available to the evaluators, which is perhaps a
result of its retrospective design. This situation, however,
reflects the information generally available in clinical
practice in these settings. Other regions where NCC is
endemic (eg, parts of Asia and Africa) were not included,
where the clinical, immunological, and imaging charac-
teristics of NCC may differ. To address this, it will be
important to validate these diagnostic criteria in these
regions in the future.
In conclusion, the new diagnostic criteria are reli-
able and valid not only for diagnosis of parenchymal
NCC, but also for the diagnosis of extraparenchymal
NCC and represent a valuable tool for clinical practice
and research. The simplicity of the tool may provide an
advantage for non-neurologist physicians in endemic
countries to make an accurate diagnosis of NCC and
ultimately to be used in primary health care. Further
research is needed to improve evidence-based diagnostic
techniques, such as imaging and molecular and immuno-
logical assays for NCC. With advances in technology,
further modifications of our tool and revalidation will
become necessary.
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